Eli Lilly reported third-quarter earnings and revenue above expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro.

Shares rose more than 3% following the results.

The company raised its full-year 2025 revenue guidance to $63–63.5 billion and adjusted profit to $23–23.70 per share, up from prior estimates, CNBC has reported.

Quarterly sales for Mounjaro reached $6.52 billion, up 109% year-over-year, while Zepbound generated $3.59 billion, a 184% increase from the prior year.